NewsBenzinga아타라 바이오테라퓨틱스의 피에르 파브르 파마슈티컬스 파트너, 타벨레클루셀 생물학적 제제 허가 신청서를 FDA에 재접수 아타라 바이오테라퓨틱스의 피에르 파브르 파마슈티컬스 파트너, 타벨레클루셀 생물학적 제제 허가 신청서를 FDA에 재접수 Benzinga 2026.09.30 12:09 (GMT+0) Open on Benzinga Other news Amazon founder Bezos says AI could let Americans support a family working just three days a week Undercovered Stocks: Hess Midstream, Iovance Biotherapeutics, Netlist, And More Tibo: OpenAI Dots May Come to the EU in the Future Whale closes $110M BTC long, then opens $45.8M long on US stocks Meta: Dense Access by Claude-Related Tools Triggered Security System, Causing Instagram Account to Be Wrongly Banned Nscale's ~$30 Billion IPO Valuation Target Questioned, Some Investors Advocate $16–19 Billion
Meta: Dense Access by Claude-Related Tools Triggered Security System, Causing Instagram Account to Be Wrongly Banned